SCHEMBL2070577

SCHEMBL2070577

Cc1nc(-c2ccc(Cl)cc2)sc1COCC1CCCNC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.43
CHRNA4 P43681 2/20 0.43
PPARA Q07869 3/20 0.41
KCNH2 Q12809 1/20 0.41
FFAR1 O14842 1/20 0.40
PPARD Q03181 1/20 0.40
RAB9A P51151 2/20 0.39
NPY1R P25929 3/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
CHEK1 O14757 1/20 0.37
ALOX5 P09917 1/20 0.36
ACP1 P24666 1/20 0.36
AGER Q15109 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069857 0.83 PPARA (0.52) CHRNB2CHRNA4PPARAFFAR1PPARD
SCHEMBL2069858 0.83 PPARA (0.52) CHRNB2CHRNA4PPARAFFAR1PPARD
SCHEMBL2070135 0.80 FFAR1 (0.41) PPARAFFAR1PPARDRAB9AALOX5
SCHEMBL2069661 0.78 CHRNB2 (0.53) CHRNB2CHRNA4KCNH2NPY1RCHRM2
SCHEMBL2069652 0.75 MAPT (0.57) PPARARAB9ANPY1RCHEK1KDM4E
SCHEMBL2069572 0.73 CHEK1 (0.49) PPARAFFAR1RAB9ACHEK1KDM4E
SCHEMBL2069079 0.73 PPARA (0.48) PPARAFFAR1PPARDAGER
SCHEMBL3889664 0.73 TP53 (0.46) PPARAFFAR1RAB9ACHEK1KDM4E
SCHEMBL2071887 0.73 PPARA (0.57) PPARAPPARDRAB9AKDM4ENPC1
SCHEMBL2069793 0.73 PPARA (0.49) PPARAKCNH2FFAR1PPARDALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20090036489-A1 Novel Cyclic Aminophenylalkanoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036489-A1 Novel Cyclic Aminophenylalkanoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036489-A1 Novel Cyclic Aminophenylalkanoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2009-02-05 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036489-A1 Novel Cyclic Aminophenylalkanoic Acid Derivative PPARA, PPARD, PPARG CHRNB2 3038/4885CHRNA4 2101/4885PPARA 1/4885
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD CHRNB2 2812/4885CHRNA4 1509/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.